Revance Therapeutics | 营业费用

Operating Expenses 更改 日
ALKERMES USD 337.09M 41.11M 2023-09
Eli Lilly USD 6.97B 2.08B 2023-12
Neurocrine Biosciences USD 357.6M 21.5M 2023-09
Pacira USD 148.08M 1.87M 2023-12
Supernus Pharmaceuticals USD 165.31M 19.57M 2023-12



Revance Therapeutics 营业费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Apr 2024.